Treatment with CAN-2409, an off-the-shelf immunotherapy, elicited responses among patients with pretreated stage 3/4 non–small cell lung cancer.

MSD says the drug could give second line patients as much as 11 months longer compared to standard therapy docetaxel (between ... to be more than 3 months. Lung cancer kills more people ...

The NMPA approval is based on the results of the OptiTROP-Lung03 trial, which compared sac-TMT monotherapy to chemotherapy with docetaxel ... in this type of lung cancer. The approval is also ...

Adding pembrolizumab to docetaxel did not significantly improve outcomes in previously treated patients with mCRPC.

Brain metastases from prostate cancer (PC) seem to be more frequent ... resistant PC have prolonged their survival. Furthermore, docetaxel (the drug of choice for the first-line treatment of ...

Final phase 2a results showed that CAN-2409 led to a median overall survival of 24.5 months in immune checkpoint ...

open-label Phase 2 trial evaluating the efficacy and safety of Olvi-Vec & Platinum-doublet + physician's choice of immune checkpoint inhibitor compared to docetaxel in non-small-cell lung cancer. The ...